This page provides information about McKinsey & Company’s past work for opioid manufacturers and its response to related issues.

McKinsey has reached agreements with all 50 State Attorneys General, as well as five US territories and the District of Columbia, resolving matters related to our past work for opioid manufacturers. McKinsey first entered into agreements with 49 State Attorneys General, the District of Columbia and five US territories on February 4, 2021. On March 22, 2021, the firm reached a similar agreement with the State of Nevada.

We recognize that our work for opioid manufacturers, while lawful, fell short of the high standards we set for ourselves and that we did not adequately acknowledge the epidemic unfolding in communities across the country. We decided nearly two years ago to end all work on opioid-specific business and have committed to being part of the solution to this serious challenge.

McKinsey has continued to take steps to strengthen its client selection policies, professional standards, and its risk and governance processes to ensure our work is consistent with our values and commitment to social responsibility.

More information about the settlement and changes to our client selection process can be found below.